1st October 2021

Strategic And Operational Progress At Creo Medical

The chief executive of Creo Medical Group has hailed the strategic and operational progress made at the listed medical device company, despite the challenges preseneted by the Covid pandemic.

In accounts covering the six months to 30 June, Creo said it had grown its clinical network and education of early adopters, while also strengthening its commercial infrastructure and making continued progress on R&D.

Total sales in the period were £12.9m.

Chief executive Craig Gulliford said: “Our focus on clinical education, both remotely and in-person, has led to more KOLs (key opinion leaders) being trained on the safe use of our products and more patients being successfully treated with our technology; Speedboat Inject has continued to be used successfully in both POEM and SSD procedures during the period.

“We expect this positive trend to remain in H2 and into 2022 as the pandemic eases, with increasing clinician education, training sites, adoption and patient procedures using our technology.”

He added: “The publication of further health economics data has underlined the potential of our Speedboat Inject technology to save costs for healthcare systems to a greater extent than first envisaged. The first patient to undergo a procedure using MicroBlate Fine has shown an excellent result, further validating the clinical use of that device.

“With the business ready to service the rising demand we expect for all our products and our strengthened balance sheet following the completion of the placing and open offer in September 2021 will allow us to deliver and develop our strategic objectives.

“We are very optimistic for the continued progress of the business throughout 2021 and into 2022.”